Klotho Neurosciences, Inc. 8-K

What Happened
Klotho Neurosciences, Inc. (KLTO) announced in an 8-K filed March 2, 2026 that it closed a private placement under a Securities Purchase Agreement dated February 19, 2026. At closing the company issued an aggregate of 34,551,939 shares of common stock and warrants to purchase up to 34,551,939 additional shares, generating approximately $7,750,000 in gross proceeds. The Securities Purchase Agreement and Form of Warrant were included in earlier 8-K disclosures (filed Feb 24, 2026).

Key Details

• Issuance: 34,551,939 shares of common stock and warrants to purchase up to 34,551,939 shares.
• Proceeds: Approximately $7,750,000 in gross proceeds to the company.
• Transaction dates/documents: Securities Purchase Agreement dated February 19, 2026; closing reported in 8-K filed March 2, 2026; warrant terms described in 8-K filed Feb 24, 2026.
• Regulatory treatment: Securities issued in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D; purchasers represented they are accredited investors, securities sold without general solicitation and for investment (not distribution).

Why It Matters
This transaction provides Klotho with additional capital (roughly $7.75M), which supports the company's operations or development needs. The issued common shares increased the share count immediately, and the attached warrants give purchasers the right to buy up to the same number of shares in the future—meaning potential further dilution if those warrants are exercised. The sale was a private, accredited-investor financing conducted under Reg D exemptions, so the securities were not registered for public resale.